LifeMine Therapeutics
Develops fungal genome-derived therapeutics for organ transplant rejection
$263MSeries D+Series E
Role not disclosedLoading investors…
Activity from announced rounds
Develops fungal genome-derived therapeutics for organ transplant rejection
Develops automated cell therapy manufacturing platforms
Develops photonic AI inference chips for data centers
Pitching Gates Frontier? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room